

FORM 7

MONTHLY PROGRESS REPORT

For July 2020

Name of Listed Issuer: Liberty Health Sciences Inc. (the "Issuer" or "Company").

Trading Symbol: LHS

Number of Outstanding Listed Securities: 346,090,635 common shares

Date: August 7, 2020

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On July 14th, the company announced it plans to open its 26th medical marijuana dispensary in Florida on July 18, 2020. The new retail location in Jacksonville Beach will serve the communities of Mayport, Atlantic Beach, Neptune Beach, and Ponte Vedra Beach, subject to approval from the Florida Department of Health. Located on the Duval County coast at 1222 South Third Street, Jacksonville Beach, FL. 32250, the dispensary is conveniently positioned along what is affectionately called northeast Florida's "First Coast" and features a 4,700 square foot store that includes a spacious display and retail area, two private consultation rooms and an expansive waiting area. The dispensary's operating hours are Monday through Friday, 10 a.m. to 7 p.m., Saturday, 10 a.m. to 5 p.m., and Sunday, 12 p.m. to 5 p.m. As with all Liberty locations, the Jacksonville Beach store showcases original paintings and photographs from talented, local artists on a rotating basis.

On July 30th, the company announced its financial results for the first quarter ended May 31, 2020. Consolidated net sales for the quarter ended May 31, 2020 were \$18,440,756, compared with \$5,520,561 for the quarter ended May 31, 2019. For the quarter ended May 31, 2020, the Company reported Adjusted EBITDA of \$4,583,269, compared with negative Adjusted EBITDA of \$3,646,809 for the quarter ended May 31, 2019. As Liberty continues to accelerate expansion of new dispensary locations, the Company has increased its cultivation and processing capacity on its 387-acre state-of-the-art Liberty-360 facility, which is comprised of 300,000 square feet of greenhouse processing and production space.

2. Provide a general overview and discussion of the activities of management.

In Florida, in addition to initiating production expansion activities at its Liberty 360° Innovation Campus in Gainesville, management continues to seek and open potential dispensary sites.

3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report in the month of July.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report in the month of July.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None to report in the month of July.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report in the month of July.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to report in the month of July.

8. Describe the acquisition of new customers or loss of customers.

The Company continues to grow its number of patients as the overall Florida market increases in terms of registered patients and as the Company expands its footprint in the state. The Florida market has also reacted positively to Liberty's whole flower products and continues to assist to expand Liberty's customer base.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None to report in the month of July.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

The Company continues to add personnel in the areas of patient care and processing in the Florida operations and dispensaries with the expected opening of additional dispensaries over the next 30-60 days.

There were no significant terminations or lay-offs in the month of July.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report in the month of July.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report in the month July.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

No new debt to report for the month of July.

14. Provide details of any securities issued and options or warrants granted.

None to report in the month July.

15. Provide details of any loans to or by Related Persons.

None to report in the month of July.

16. Provide details of any changes in directors, officers, or committee members.

None to report in the month July.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

In a highly unusual move, the Florida Supreme Court on July 14th ordered a second round of arguments in a battle about whether the state has properly carried out a 2016 constitutional amendment that broadly legalized medical marijuana. Justices heard arguments in May in a lawsuit filed by Florigrown, a Tampa-based firm that has challenged the constitutionality of a 2017 law that was designed to carry out the constitutional amendment. The case centers on parts of the law related to the licensing of companies to operate in the medical-marijuana industry. But the Supreme Court on July 14th issued an order scheduling another round of arguments Oct. 7 on an issue that was not a focus of the first hearing — whether the 2017 law is what is known as an unconstitutional “special” law. The Florida Constitution bars “special” laws that, generally, are intended to benefit specific entities. Florigrown, which has unsuccessfully sought a medical-marijuana license, contends that parts of the 2017 law improperly limited the firms that could take part in the industry.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. To the best of the undersigned's knowledge and belief, as of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that, to the best of the undersigned's knowledge and belief, the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. To the best of the undersigned's knowledge and belief, all of the information in this Form 7 Monthly Progress Report is true.

Dated August 7, 2020.

Sheri Cholodofsky

Name of Director or Senior Officer

"Sheri Cholodofsky"

Signature

CFO

Official Capacity

Issuer Details		For Month End	Date of Report YY/MM/DD
Name of Issuer Liberty Health Sciences Inc.		July 31, 2020	20/08/07
Issuer Address 78 Gwendolen Crescent			
City/Province/Postal Code Toronto, ON, Canada M2N 2L7		Issuer Fax No.	Issuer Telephone No.
Contact Name Sheri Cholodofsky		Contact Position CFO	Contact Telephone 833 254 4877
Contact Email Address ir@libertyhealthsciences.com		Web Site Address https://libertyhealthsciences.com/	